These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22433870)

  • 1. Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).
    Shajahan AN; Dobbin ZC; Hickman FE; Dakshanamurthy S; Clarke R
    J Biol Chem; 2012 May; 287(21):17682-17692. PubMed ID: 22433870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity.
    Shajahan AN; Wang A; Decker M; Minshall RD; Liu MC; Clarke R
    J Biol Chem; 2007 Feb; 282(8):5934-43. PubMed ID: 17190831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast cancer cells: role of autophagy and JNK activation.
    Notte A; Ninane N; Arnould T; Michiels C
    Cell Death Dis; 2013 May; 4(5):e638. PubMed ID: 23681233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells.
    Shiah SG; Chuang SE; Kuo ML
    Mol Pharmacol; 2001 Feb; 59(2):254-62. PubMed ID: 11160861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caveolin-1 regulates cell apoptosis and invasion ability in paclitaxel-induced multidrug-resistant A549 lung cancer cells.
    Han F; Zhang L; Zhou Y; Yi X
    Int J Clin Exp Pathol; 2015; 8(8):8937-47. PubMed ID: 26464635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL2 and BCLxL are key determinants of resistance to antitubulin chemotherapeutics in melanoma cells.
    Watanabe A; Yasuhira S; Inoue T; Kasai S; Shibazaki M; Takahashi K; Akasaka T; Masuda T; Maesawa C
    Exp Dermatol; 2013 Aug; 22(8):518-23. PubMed ID: 23802633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
    Wang Z; Goulet R; Stanton KJ; Sadaria M; Nakshatri H
    Anticancer Res; 2005; 25(3c):2367-79. PubMed ID: 16080463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cells.
    Wang S; Wang Z; Dent P; Grant S
    Blood; 2003 May; 101(9):3648-57. PubMed ID: 12522001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
    Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
    Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling.
    Ravid D; Maor S; Werner H; Liscovitch M
    Oncogene; 2005 Feb; 24(8):1338-47. PubMed ID: 15592498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.
    Fresquet V; Rieger M; Carolis C; García-Barchino MJ; Martinez-Climent JA
    Blood; 2014 Jun; 123(26):4111-9. PubMed ID: 24786774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Astragaloside IV enhances taxol chemosensitivity of breast cancer via caveolin-1-targeting oxidant damage.
    Zheng Y; Dai Y; Liu W; Wang N; Cai Y; Wang S; Zhang F; Liu P; Chen Q; Wang Z
    J Cell Physiol; 2019 Apr; 234(4):4277-4290. PubMed ID: 30146689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells.
    Ajabnoor GM; Crook T; Coley HM
    Cell Death Dis; 2012 Jan; 3(1):e260. PubMed ID: 22278287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor suppressor BLU promotes paclitaxel antitumor activity by inducing apoptosis through the down-regulation of Bcl-2 expression in tumorigenesis.
    Park ST; Byun HJ; Kim BR; Dong SM; Park SH; Jang PR; Rho SB
    Biochem Biophys Res Commun; 2013 May; 435(1):153-9. PubMed ID: 23628417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen inhibits paclitaxel-induced apoptosis via the phosphorylation of apoptosis signal-regulating kinase 1 in human ovarian cancer cell lines.
    Mabuchi S; Ohmichi M; Kimura A; Nishio Y; Arimoto-Ishida E; Yada-Hashimoto N; Tasaka K; Murata Y
    Endocrinology; 2004 Jan; 145(1):49-58. PubMed ID: 14500571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival.
    Wu W; Pew T; Zou M; Pang D; Conzen SD
    J Biol Chem; 2005 Feb; 280(6):4117-24. PubMed ID: 15590693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
    Chang J; Sui M; Fan W
    Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel.
    Zhao W; Song Y; Xu B; Zhan Q
    Cancer Biol Ther; 2012 Feb; 13(3):156-63. PubMed ID: 22353935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1.
    Wang MY; Chen PS; Prakash E; Hsu HC; Huang HY; Lin MT; Chang KJ; Kuo ML
    Cancer Res; 2009 Apr; 69(8):3482-91. PubMed ID: 19351859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.